ProCE Banner Activity

How I Use Individual PK Profiling to Personalize Hemophilia Prophylaxis

Clinical Thought
Our current goals for managing hemophilia have evolved beyond simply preventing bleeding and joint damage—now, we aim to give our patients as full a life as would be possible without hemophilia. Read my take on leveraging extended half-life products and tools for estimating PK profiles to individualize hemophilia prophylaxis.

Released: November 20, 2020

Expiration: November 19, 2021

Share

Faculty

Michael Callaghan

Michael Callaghan, MD

Associate Professor
Department of Hematology
Wayne State University
Hematologist
Division of Hematology/Oncology
Childrens Hospital of Michigan
Detroit, Michigan

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Takeda Pharm USA

Faculty Disclosure

Primary Author

Michael Callaghan, MD

Associate Professor
Department of Hematology
Wayne State University
Hematologist
Division of Hematology/Oncology
Childrens Hospital of Michigan
Detroit, Michigan

Michael Callaghan, MD, has disclosed that he has received consulting fees from Bayer, BioMarin, Catalyst, Hema Biologics, Roche/Genentech, Sanofi, Spark, and Takeda.